Interferon News and Research

RSS

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Medivir AB today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 hepatitis C patients.

23 Apr 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.

23 Apr 2013

Researchers decipher the underlying mechanism of antiviral drug

A long-forgotten candidate for antiviral therapy is undergoing a renaissance: Since the 1970s, the small molecule CMA has been considered a potent agent against viral infections, yet it was never approved for clinical use.

22 Apr 2013

BIIR researchers report results of comparative study of molecular immune responses to influenza and pneumococcal vaccines

In a manuscript published today in Immunity, scientists at the Baylor Institute for Immunology Research (BIIR) and the Benaroya Research Institute at Virginia Mason report the results of a comparative study of the molecular immune responses to influenza and pneumococcal vaccines.

19 Apr 2013

Ribavirin, interferon-alpha 2b inhibit virus replication in cell culture, NIH study finds

National Institutes of Health scientists studying an emerging coronavirus have found that a combination of two licensed antiviral drugs, ribavirin and interferon-alpha 2b, can stop the virus from replicating in laboratory-grown cells.

19 Apr 2013

Researchers propose strategies for improving the anti-cancer effects of interferon

Interferons have antitumor activity and have been used to treat a variety of malignancies, including colorectal and ovarian cancers.

18 Apr 2013

Findings hold promise for development of therapies to fight different viral infections

The human body has the ability to ward off viruses by activating a naturally occurring protein at the cellular level, setting off a chain reaction that disrupts the levels of cholesterol required in cell membranes to enable viruses to enter cells.

18 Apr 2013

New approaches to treat persistent viral infections like HIV and hepatitis C

UCLA scientists have shown that temporarily blocking a protein critical to immune response actually helps the body clear itself of chronic infection. Published in the April 12 edition of Science, the finding suggests new approaches to treating persistent viral infections like HIV and hepatitis C.

12 Apr 2013

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

11 Apr 2013

Boehringer Ingelheim's STARTVerso 1 Phase 3 hepatitis C data to be presented at EASL Congress

Boehringer Ingelheim today announced that data from its pivotal STARTVerso 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress 2013: 48th Annual Meeting of the European Association for the Study of the Liver, taking place from April 24-28 in Amsterdam, The Netherlands.

10 Apr 2013

Gilead Sciences submits sofosbuvir NDA to FDA for treatment of chronic HCV infection

Gilead Sciences today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration for approval of sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus infection.

9 Apr 2013

Phase 3 study results of simeprevir in hepatitis C patients to be presented at EASL Congress

Janssen R&D Ireland announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver, which will take place April 24 to 28 in Amsterdam, The Netherlands.

8 Apr 2013

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Bristol-Myers Squibb Company announced today that 14 abstracts on the Company's research in liver disease have been accepted for presentation at The International Liver CongressTM 2013, the 48th annual meeting of the European Association for the Study of the Liver, in Amsterdam, April 24 - 28.

8 Apr 2013

Inovio Pharmaceuticals reports release of phase II clinical trial results of ChronVac-C

Inovio Pharmaceuticals, Inc. today announced the release of preliminary clinical trial results by its collaborator ChronTech AS of their open label phase II clinical study of ChronVac-C, ChronTech's vaccine to treat hepatitis C virus infection.

2 Apr 2013

Scientists get inside look at how AIDS virus grooms its assault team

A new study by Los Alamos National Laboratory and University of Pennsylvania scientists defines previously unknown properties of transmitted HIV-1, the virus that causes AIDS.

2 Apr 2013

Medivir seeks FDA approval for simeprevir

Medivir AB today announced that a new drug application has been filed with the U.S. Food and Drug Administration seeking approval for simeprevir.

30 Mar 2013

Research findings could lead to new treatments for lung disorders in premature babies

Researchers at Yale School of Medicine have made major discoveries that could lead to new treatments for lung disorders in premature babies. In a mouse study, the team located key molecules that switch on stress pathways in preterm lung disorders, and also found that when parts of these pathways were blocked with a pain drug, lung damage was prevented or reversed.

21 Mar 2013

Hepatitis C and HIV co-infection treatment: an interview with Prof Boecher, Boehringer Ingelheim

Chronic hepatitis C infection is one of the most frequent chronic infectious diseases worldwide. The WHO estimates that 150 million people worldwide are chronically infected with the hepatitis C virus (HCV).

20 Mar 2013

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

...

14 Mar 2013

Interferon News and Research

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Researchers decipher the underlying mechanism of antiviral drug

BIIR researchers report results of comparative study of molecular immune responses to influenza and pneumococcal vaccines

Ribavirin, interferon-alpha 2b inhibit virus replication in cell culture, NIH study finds

Researchers propose strategies for improving the anti-cancer effects of interferon

Findings hold promise for development of therapies to fight different viral infections

New approaches to treat persistent viral infections like HIV and hepatitis C

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Boehringer Ingelheim's STARTVerso 1 Phase 3 hepatitis C data to be presented at EASL Congress

Gilead Sciences submits sofosbuvir NDA to FDA for treatment of chronic HCV infection

Phase 3 study results of simeprevir in hepatitis C patients to be presented at EASL Congress

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Inovio Pharmaceuticals reports release of phase II clinical trial results of ChronVac-C

Scientists get inside look at how AIDS virus grooms its assault team

Medivir seeks FDA approval for simeprevir

Research findings could lead to new treatments for lung disorders in premature babies

Hepatitis C and HIV co-infection treatment: an interview with Prof Boecher, Boehringer Ingelheim

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News